Adenosine receptor ligands as potential therapeutics in asthma.
Increasingly persuasive evidence implicates adenosine in the pathophysiology of asthma. Adenosine exerts its manifold biological activities by interacting with at least four adenosine receptor subtypes. Selective activation or blockade of these sites is being exploited by the pharmaceutical industry in an attempt to generate novel therapies for asthma. Compounds have been designed which downregulate the A1 receptor, activate the A2A receptor or block the A2B receptor and are currently in development for this condition.
Fozard
John R
JR
Research Department, Novartis Pharma AG, Basel, Switzerland. john_r.fozard@pharma.novartis.com
McCarthy
Clive
C
D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008024:Ligands; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods / Q000706:statistics & numerical data
D008024:Ligands; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1